In my opinion I think this is a really good news. Wouldn't it be easier for a country, for example the UK, Spain, Italy... and Australia (which is already included in the trial) to approve the treatment if they have the evidence that the product has been trialed at their own country and not just the US?
Given the different strains of Covid-19 in different countries and regions, this would give more data to support the approval of Remestemcel_L.
Cell Therapy News/Articles, page-7704
-
- There are more pages in this discussion • 10,107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |